Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
50.90
+1.12 (2.25%)
At close: Aug 13, 2025, 4:00 PM
51.08
+0.18 (0.35%)
After-hours: Aug 13, 2025, 7:18 PM EDT
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$634,901
Profits / Employee
$226,061
Market Cap
227.37B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
Dec 31, 2019 | 43,258 | 56 | 0.13% |
Dec 31, 2018 | 43,202 | 520 | 1.22% |
Dec 31, 2017 | 42,682 | 711 | 1.69% |
Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
Dec 31, 2015 | 40,638 | -319 | -0.78% |
Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
Dec 31, 2003 | 18,756 | 751 | 4.17% |
Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
Dec 31, 1999 | 11,994 | 345 | 2.96% |
Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NVO News
- 5 hours ago - A Cure For Novo Nordisk - Seeking Alpha
- 8 hours ago - Novo Nordisk: The Falling Knife That Keeps Giving - Seeking Alpha
- 2 days ago - Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies? - Fast Company
- 2 days ago - Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes - Seeking Alpha
- 2 days ago - Novo Nordisk: Enough Is Enough - Seeking Alpha
- 2 days ago - Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities - Seeking Alpha
- 2 days ago - As Novo Nordisk ramps up lawsuits over Wegovy copies, investors ask where is Hims? - Reuters
- 3 days ago - Why I Tripled My Novo Nordisk Position - Seeking Alpha